Value-Based Pharma R&D Productivity: Is There A Sweet Spot?
What do Gilead, Biogen, and Celgene have in common? Qualities to be the top three drugmakers ranked by both R&D productivity and growth, according to a novel method for measuring such criteria that management consulting firm Catenion says offers insights for achieving such success.
You may also be interested in...
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.
Catenion, a biopharma-focused R&D strategy consulting firm, has analyzed the performance of the top-30 biopharma companies in 2018 and outlined major concerns for the future of innovation in drug development.
To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion takes an approach that focuses on value.